RxDoctor Payments Data

Georgy Kaspar

Internal Medicine · Boynton Beach, FLNPI 1407138654

Payments from drug & device makers

$12,529in general payments, 2019–2025

Across 267 payments — averaging $46.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Boston Scientific$4K
  • Medtronic$1K
  • Amgen$444
  • Johnson & Johnson$359
  • Novartis$323
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$270%
  • Travel & lodging$5,10241%
  • Food & beverage$7,37959%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,529 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$241,586
Medicare patients
1,405
Services billed
4,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban402$304,422
XareltoRivaroxaban243$157,654
JardianceEmpagliflozin213$153,924
EntrestoSacubitril/Valsartan94$78,978
Repatha SureclickEvolocumab126$73,732
FarxigaDapagliflozin Propanediol38$20,797
Praluent PenAlirocumab21$10,059
Atorvastatin Calcium552$6,893
Ranolazine ErRanolazine64$4,997
Flecainide Acetate94$4,862
Droxidopa13$4,744
Metoprolol Succinate255$4,261
Carvedilol382$4,033
Midodrine Hcl23$3,697
Losartan Potassium218$2,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$304,422402 claims
Johnson & JohnsonXarelto$359$157,654243 claims
Boehringer IngelheimJardiance$118$153,924213 claims
NovartisEntresto$323$78,97894 claims
AstraZenecaFarxiga$121$20,79738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →